| abstract |
Compounds of general structure (a) and (b) are disclosed, wherein X is O, Cn, NH, or S, wherein n is 1, 2, 3 or 4; R1 is OH, CH3, CH2OH, N3 or CH2N3; R3 is H or CH3; R5 is Y-R2, wherein Y is a six-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum of three; R2 is C1-C10 alkyl OH, C1-C10 alkyl N3 or COOR4, wherein R4 is H, a branched or unbranched C1-C10 alkyl (including substituted alkyl radicals), cycloalkyl, preferably C5 OC C6 cycloalkyl, or a five- or six-membered aryl radical (including substituted aryl radicals), i.e. R2 is COOH or an ester of R4; R6 is a seven-carbon chain optionally containing up to three double or triple bonds or a mixture of double and triple bonds up to a maximum or three; and (c) indicates a single, double or triple bond. The compounds are analogs of hepoxilins and are used to modulate hepoxilin activity, for example in the control of inflammation or other processes mediated by intracellular calcium levels. |